JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

NCT06838338 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: JAB-21822
DRUG: standard second-line chemotherapy
DRUG: Bevacizumab

Sponsor

Jian Li